<DOC>
	<DOC>NCT01414257</DOC>
	<brief_summary>This Investigation is to be performed for the purpose of assessing the following information in the long-term post-marketing daily medical practice in the patients who receive REUMATOLEX 2 mg Capsule for the treatment of Rheumatoid Arthritis (RA) at the dose higher than 8 mg/week. 1. Condition of occurrence of ADRs 2. Factors considered to affect safety 3. Verification of efficacy</brief_summary>
	<brief_title>Methotrexate (Rheumatrex) High Dose Special Investigation (Regulatory Post Marketing Commitment Plan)</brief_title>
	<detailed_description>Implemented as a Special Investigation by Central Registration System</detailed_description>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Patients need to be administered Rheumatrex in order to be enrolled in the survey Patients who receive the Rheumatrex at the dose higher than 8 mg/week for the treatment of Rheumatoid Arthritis Patients who have been treated with Rheumatrex at the dose higher than 8 mg/week since the days when the high dose therapy for RA was not approved Patients who have been treated MTX other than Rheumatrex administered Rheumatrex</criteria>
	<gender>All</gender>
	<minimum_age>17 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Rheumatrex</keyword>
	<keyword>High Dose</keyword>
</DOC>